NCT00387153View on ClinicalTrials.gov

Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Cancer
Interventions
DRUG

MPC-2130

MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Myriad Therapeutics, Inc.

INDUSTRY